Andexxa market forecast points to stronger demand through 2030

The Business Research Company says the global Andexxa (Ondexxya) market is set to grow through 2030 as bleeding disorders, anticoagulant use and emergency reversal needs rise. North America led in 2025, while Europe is expected to post the fastest growth over the forecast period.

Why it matters: - Andexxa is used to reverse the effects of Factor Xa blood thinners in life-threatening or uncontrolled bleeding. - The market outlook reflects growing demand for rapid anticoagulant reversal in hospitals, trauma care and emergency settings. - Rising bleeding disorder cases and an aging population are expanding the patient pool that may need reversal therapy.

What happened: - The Business Research Company released a 2026 market report on the global Andexxa (Ondexxya) market and its forecast to 2030. - The report says the market has been supported by factor Xa inhibitor use, emergency bleeding events, regulatory approvals for reversal agents, hospital critical care demand and an aging population. - The report says the market is being driven forward by higher cardiovascular disease prevalence, more anticoagulant prescriptions, more trauma care, improved emergency protocols and more surgical procedures. - The report identifies North America as the largest regional market in 2025. - The report projects Europe as the fastest-growing region over the forecast period.

The details: - Andexxa (Ondexxya) reverses Factor Xa inhibitors including rivaroxaban (Xarelto) and apixaban (Eliquis). - The drug is positioned for situations where immediate anticoagulation reversal is critical. - The report says key trends include rising demand for anticoagulant reversal, advances in emergency bleeding management, continued use of Factor Xa inhibitors and a focus on rapid hemostasis solutions. - The report says regional coverage also includes Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - In July 2025, the National Blood Authority in Australia reported 2,797 patients living with von Willebrand disease in 2023-2024, up from 2,669 the prior year. - A World Health Organization report from October 2022 said one in six people globally will be 60 or older by 2030, and that number is expected to reach 2.1 billion by 2050. - The report says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies and updated graphics and tables. - The report offers a free sample at the company’s sample request page. - The full report is available at the company’s market report page.

Between the lines: - The market thesis is tied less to broad drug adoption and more to the growing frequency of high-risk clinical situations where rapid reversal can be decisive. - Aging populations matter because older patients are more likely to receive anticoagulants for conditions such as atrial fibrillation, which raises potential demand for reversal agents. - The regional split suggests the market is already established in North America, while Europe may be earlier in the growth curve.

What's next: - Demand is likely to track the pace of anticoagulant prescribing, surgical volumes and emergency care protocols through 2030. - Wider awareness of bleeding disorders and continued development of hospital critical care workflows could support further market expansion. - More details and market updates are available through The Business Research Company.